30
ULTRATHERM 908i
gbo Medizintechnik AG 2004
Version 1.6
Appendix B: Treatment table
In the table, the doses are stated according to Schliephake, who distinguishes between four
stages:
Dose I
No perceptible heat. First set output to low perception of heat and then turn
slightly down.
Dose IIBarely perceptible heat.
Dose III
Perceptible agreeable heat.
Dose IV
Still bearable heating.
In the event of exacerbation, pauses should be made and treatment continued with reduced
intensity. Chronic processes of the skeletal system call for stronger applications of heat.
Disease:
Electrodes
preferred: *
Dose acc. to
Schliephake:
Treatment
time (min):
Frostbite, local, acute
WE; SE; WE+SE; M
I
3 - 8
Frostbite, local, chronic
WE; SE; WE+SE; M
I - II
10
Erythema
M, DI
I - II
5 - 10
Furuncle, carbuncle
M
I - II
3 - 5
Hydradenitis
SE, M
II
10
Panaritia
WE, M, DI
I - II
5 - 10
Arthritis
SE, DI
II - III
10 - 15
Bursitis
M
II - III
10
Sprains, contusions
SE, DI
II - III
5 - 10
Epicondylitis
M
II - III
10 - 20
Lumbago
DI
II - III
10 - 20
Bechterew’s disease
SE, DI
II - III
10 - 20
Myalgia
WE, SE, DI
I - III
10 - 20
Periarthritis
SE, M, DI
II - III
10 - 20
Periostitis
WE, SE, WE + SE, DI II - III
5 - 10
Polyarthritis
SE, DI
II - III
5 - 10
Spondylosis
WE, SE, DI
II - III
15 - 20
Tendovaginitis
SE, M
II - III
10 - 15
Sciatica, acute
WE, SE
I - II
5 - 8
Sciatica, chronic
WE, SE
II - III
10 - 20
Neuralgias
WE, SE, DI
I - III
5 - 15
Neuritis
WE, SE, DI
I - III
3 - 15
Angina pectoris (dose carefully)
WE, SE, DI
II
3 - 5
Impaired peripheral circulation
WE, SE
II -III
10 - 15
Thrombophlebitis
WE, SE
II
5 - 10
